This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Otonomy Past Earnings Performance
Past criteria checks 0/6
Key information
11.1%
Earnings growth rate
28.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -48.0% |
| Return on equity | -244.2% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails
Aug 01Otonomy GAAP EPS of -$0.19 beats by $0.01
Jul 25Otonomy: Hearing Loss And Tinnitus Data In 2022
Apr 04Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being
Jun 16
Otonomy shares rise after initiating expansion of early-stage OTO-413 hearing loss trial
Jun 15Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?
Feb 02Otonomy And Its Efforts At Resurrecting Itself
Jan 12Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?
Dec 11Otonomy (OTIC) Investor Presentation - Slideshow
Dec 02Otonomy issues update for Otividex and OTO-313
Nov 30Revenue & Expenses BreakdownBeta
Revenue & Expenses Breakdown
BetaHow Otonomy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -52 | 14 | 35 |
| 30 Jun 22 | 0 | -53 | 14 | 37 |
| 31 Mar 22 | 0 | -53 | 14 | 36 |
| 31 Dec 21 | 0 | -51 | 15 | 35 |
| 30 Sep 21 | 0 | -48 | 15 | 31 |
| 30 Jun 21 | 0 | -46 | 15 | 29 |
| 31 Mar 21 | 0 | -45 | 15 | 28 |
| 31 Dec 20 | 0 | -45 | 15 | 28 |
| 30 Sep 20 | 0 | -45 | 15 | 29 |
| 30 Jun 20 | 0 | -44 | 13 | 30 |
| 31 Mar 20 | 1 | -44 | 12 | 32 |
| 31 Dec 19 | 1 | -45 | 12 | 33 |
| 30 Sep 19 | 1 | -47 | 13 | 35 |
| 30 Jun 19 | 1 | -49 | 16 | 36 |
| 31 Mar 19 | 1 | -51 | 19 | 35 |
| 31 Dec 18 | 1 | -50 | 20 | 32 |
| 30 Sep 18 | 1 | -56 | 22 | 28 |
| 30 Jun 18 | 1 | -65 | 28 | 31 |
| 31 Mar 18 | 1 | -74 | 34 | 35 |
| 31 Dec 17 | 1 | -90 | 43 | 43 |
| 30 Sep 17 | 1 | -98 | 48 | 51 |
| 30 Jun 17 | 1 | -104 | 49 | 55 |
| 31 Mar 17 | 1 | -111 | 51 | 59 |
| 31 Dec 16 | 1 | -111 | 50 | 60 |
| 30 Sep 16 | 0 | -105 | 45 | 59 |
| 30 Jun 16 | 0 | -94 | 40 | 53 |
Quality Earnings: OTIC is currently unprofitable.
Growing Profit Margin: OTIC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OTIC is unprofitable, but has reduced losses over the past 5 years at a rate of 11.1% per year.
Accelerating Growth: Unable to compare OTIC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OTIC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.6%).
Return on Equity
High ROE: OTIC has a negative Return on Equity (-244.24%), as it is currently unprofitable.